Tyrosine kinase inhibitors are associated with reduced AML transformation in systemic mastocytosis with myeloid neoplasm.

KIT D816V-selective tyrosine kinase inhibitor exposure in 201 patients with SM-AHN is linked to longer overall survival (37.9 vs 17.8 months) and reduced AML transformation at 36 months (5.9% vs 27.1%).

• Why it matters: Systemic mastocytosis with an associated myeloid neoplasm has a high risk of progressing to acute myeloid leukemia, and outcomes vary without clear prognostic guidance.
• What they did: An international registry analysis of 201 patients with SM-AHN evaluated whether KIT D816V-selective TKI exposure related to survival and the 36-month incidence of AML transformation.
• The result: KIT D816V-selective TKI exposure is associated with improved overall survival and a lower 36-month AML transformation incidence, suggesting a protective link in this registry cohort.

AI summary of the abstract · may contain errors · not medical advice · read the paper.